RSS

small-molecule therapeutics

Private therapeutics company, Inflection Biosciences, has published preclinical data, demonstrating that its dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise for the treatment of chronic lymphocytic leukaemia (CLL). Read more

News